glp·helper
glphelper.com/zepbound/florida/pembroke-pines
Dual GIP / GLP-1 receptor agonistFDA-approved November 2023Rx · Subcutaneous injection · Once weekly

Zepbound® providers &
prescriptions in Pembroke Pines, FL

Verified Zepbound providers in Pembroke Pines, FL. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Zepbound weight loss →trial-anchored estimate
city providers
42
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Florida
43 of 43 shown

Find a Zepbound provider in Florida.

Every entry is checked against the NPI registry and the Florida medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Florida city · /zepbound/florida/{city}
§ 03Getting Zepbound in Pembroke Pines
43 providers · Pembroke Pines, FL

How to get Zepbound in Pembroke Pines.

43 GLP-1 prescribers and 7 local resource types are on record for Pembroke Pines, plus 3 nearby towns in the directory.

Prescribers in Pembroke Pines
43 prescribers
43 GLP-1 prescribers in Pembroke Pines, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (15), Family Medicine (14) and Internal Medicine (12). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Zepbound, over video or in person. The nearest towns on record are Miramar (35 providers), Davie (35 providers) and Plantation (36 providers).
Around the prescription in Pembroke Pines
7 listed nearby
44 dietitians, 4 nutritionists, 6 gyms, 6 fitness clubs, 5 trainers, 6 physiotherapists and 6 places to move are on record near Pembroke Pines.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.

Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
November 2023
Approved use
Chronic weight management (adults with obesity, or overweight with a weight-related condition)
Off-label use
Type 2 diabetes (Mounjaro is the FDA-approved tirzepatide for diabetes)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Pembroke Pines

Pembroke Pines, Florida has a population of 171,178 people. The adult obesity rate in Pembroke Pines is an age-adjusted estimate of 28.8%, 0.8 percentage points below the Florida state rate of 29.6%. Diagnosed diabetes reaches 11.2% of adults in Pembroke Pines. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 24.6% of adults in Pembroke Pines.

of Pembroke Pines adults have obesity
28.8%
diagnosed diabetes
11.2%
no regular physical activity
24.6%

Age-adjusted estimates for Pembroke Pines, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossweight regain after stopping
§ 05Support around Zepbound in Pembroke Pines
6 gyms

The prescription is one part. Here is the rest, in Pembroke Pines.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Pembroke Pines, FL, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

LA Fitness
GYM
4.2 on Google · 1284 reviews
18445 Pines Blvd
Website
Planet Fitness
GYM
4.6 on Google · 1144 reviews
14802 Pines Blvd
Website
Crunch Fitness - West Pembroke
GYM
4.0 on Google · 712 reviews
16024 Pines Blvd
Website
Freakin Fitness Pines (24/7)
GYM
4.9 on Google · 248 reviews
200 SW 172nd Ave
Website
SWEAT440 Fitness Pembroke Pines
GYM
5.0 on Google · 140 reviews
15845 Pembroke Pines Boulevard
Website
Fordham Fitness
GYM
5.0 on Google · 38 reviews
9929 Pines Blvd

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Nancy Alexidor, RDN/LDN
RD
Registered dietitian
1621 Sw 120Th Ave
Call 954-945-0016NPI 1265293872
Novel Allen, MS, RD, LD/N
RD
Registered dietitian
12379 Pembroke Rd
Call 954-205-3296NPI 1811965023
Sonia Angel
RD
Registered dietitian
601 N Flamingo Rd Ste 408
Call 954-265-3015NPI 1831910769
Jestine Argueza, RDN, LDN
RD
Registered dietitian
851 Broken Sound Pkwy Nw Ste 250
Call 561-278-6033NPI 1972118115
Isabel Astorga, RD
RD
Registered dietitian
838 Sw 146Th Ter
Call 321-417-0464NPI 1518810928
Jodi-Ann Brown, RD
RD
Registered dietitian
1141 Sw 87Th Ave
Call 954-665-9766NPI 1518720572
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (10 mg)
−19.5%
SURMOUNT-1, 72 wk[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Zepbound weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Zepbound cash price (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Commercial insurance (weight)
Often denied
On-label for obesity but frequently requires prior authorization
Medicare Part D
Not covered
Weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance with coverage only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Zepbound providers in Florida

NPI-verified Zepbound (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Zepbound in other states

Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Zepbound in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]